{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2026-N-10429\" sorted by posted_date descending", "rows": [["FDA-2026-N-10429-0002", "FDA", "FDA-2026-N-10429", "Reference 1 - Alper, K.R., Stajic\u00b4, M., and J.R. Gill, \u2018\u2018Fatalities temporally associated with the ingestion of ibogaine,\u2019\u2019 J. Forensic Sci., 57(2):398\u2013412 (2012), available at doi:10.1111/j.1556-4029.2011.02008.x.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:11Z", null, 0, 0, "09000064b9635d74"], ["FDA-2026-N-10429-0003", "FDA", "FDA-2026-N-10429", "Reference 2 - Brunt, T.M., \u2018\u2018Rare but relevant: ibogaine and cardiovascular complications\u2014 prolonged QT interval and ventricular arrhythmias,\u2019\u2019 Addiction, 121(6):1616\u2013 1621 (2026), available at doi:10.1111/add.70319.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:30Z", null, 0, 0, "09000064b9635d75"], ["FDA-2026-N-10429-0005", "FDA", "FDA-2026-N-10429", "Reference 4 - Knuijver, T., ter Heine, R., Schellekens, A.F.A., Heydari, P., Lucas, L., et al., \u2018\u2018The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients,\u2019\u2019 J. Psychopharmacol., 38(5):481\u2013488 (2024),\navailable at doi:10.1177/02698811241237873.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:37Z", null, 0, 0, "09000064b9635d77"], ["FDA-2026-N-10429-0004", "FDA", "FDA-2026-N-10429", "Reference 3 - Knuijver, T., Schellekens, A., Belgers, M., Donders, R., van Oosteren, T., et al., \u2018\u2018Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study,\u2019\u2019 Addiction, 117(1):118\u2013128 (2022), available at doi:10.1111/add.15448.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:33Z", null, 0, 0, "09000064b9635d76"], ["FDA-2026-N-10429-0009", "FDA", "FDA-2026-N-10429", "Reference 8 - Rocha, J.M., Reis, J.A.S., Bouso, J.C., Hallak, J.E.C., and R.G. Dos Santos, \u2018\u2018Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies,\u2019\u2019 Eur. Arch. Psychiatry Clin. Neurosci., 273(7):1527\u20131542 (2023), available at doi:10.1007/s00406-023-01590-1.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:48Z", null, 0, 0, "09000064b9637d4e"], ["FDA-2026-N-10429-0008", "FDA", "FDA-2026-N-10429", "Reference 7 - Roden, D.M., \u2018\u2018Drug-induced prolongation of the QT interval,\u2019\u2019 N. Engl. J. Med., 350(10):1013\u20131022 (2004), available at doi:10.1056/NEJMra032426.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-07T23:57:35Z", null, 0, 0, "09000064b9637d4d"], ["FDA-2026-N-10429-0006", "FDA", "FDA-2026-N-10429", "Reference 5 - Kock, P., Froelich, K., Walter, M., Lang, U., and K.M. Du\u00a8 rsteler, \u2018\u2018A systematic literature review of clinical trials and therapeutic applications of ibogaine,\u2019\u2019 J. Subst. Abuse Treat., 138:108717 (2022), available at doi:10.1016/j.jsat.2021.108717.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:40Z", null, 0, 0, "09000064b9635d78"], ["FDA-2026-N-10429-0007", "FDA", "FDA-2026-N-10429", "Reference 6. - Ona, G., Rocha, J.M., Bouso, J.C., Hallak, J.E.C., Borra`s, T., et al., \u2018\u2018The adverse events of ibogaine in humans: an updated systematic review of the literature (2015\u20132020),\u2019\u2019 Psychopharmacology, 239(6):1977\u20131987\n(2022), available at doi:10.1007/s00213-021-05964-y.", "Supporting & Related Material", "Background Material", "2026-10-06T04:00:00Z", 2026, 10, null, null, "2026-10-06T20:44:43Z", null, 0, 0, "09000064b9635d79"], ["FDA-2026-N-10429-0001", "FDA", "FDA-2026-N-10429", "Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information", "Notice", "Requests for Information (RFI)", "2026-10-06T04:00:00Z", 2026, 10, "2026-10-06T04:00:00Z", "2026-11-21T04:59:59Z", "2026-10-15T09:00:40Z", "2026-20427", 1, 0, "09000064b962e7b9"]], "truncated": false, "filtered_table_rows_count": 9, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2026-N-10429"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-N-10429", "results": [{"value": "FDA", "label": "FDA", "count": 9, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-N-10429&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-N-10429", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 8, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-N-10429&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-N-10429&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-N-10429", "results": [{"value": 2026, "label": 2026, "count": 9, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-N-10429&posted_year=2026", "selected": false}], "truncated": false}}, "suggested_facets": [], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1.7762077040970325, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}